{"id":"NCT03280056","sponsor":"Brainstorm-Cell Therapeutics","briefTitle":"Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients","officialTitle":"A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-28","primaryCompletion":"2020-09-29","completion":"2020-09-29","firstPosted":"2017-09-12","resultsPosted":"2024-02-29","lastUpdate":"2024-02-29"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"BIOLOGICAL","name":"NurOwn® (MSC-NTF cells)","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Bone Marrow aspiration","otherNames":[]}],"arms":[{"label":"NurOwn® (MSC-NTF cells)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs).\n\nThe autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells","primaryOutcome":{"measure":"The Proportion of NurOwn® Treated Participants With a ≥1.25 Points/Month Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score at 28 Weeks Following the First Treatment as Compared to Placebo","timeFrame":"28 weeks following the first intrathecal injection","effectByArm":[{"arm":"NurOwn® (MSC-NTF Cells)","deltaMin":31,"sd":null},{"arm":"Placebo","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.453"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":95},"commonTop":["Procedural pain","Headache","Back pain","Fall","Procedural headache"]}}